Navigation Links
Amgen Presents Pooled Analysis Showing AMG 145 Significantly Reduced LDL Cholesterol In Over 1,200 Patients
Date:9/1/2013

ment, usage and pricing of our products. In addition, we compete with other companies with respect to some of our marketed products as well as for the discovery and development of new products. We believe that some of our newer products, product candidates or new indications for existing products, may face competition when and as they are approved and marketed. Our products may compete against products that have lower prices, established reimbursement, superior performance, are easier to administer, or that are otherwise competitive with our products. In addition, while we routinely obtain patents for our products and technology, the protection offered by our patents and patent applications may be challenged, invalidated or circumvented by our competitors and there can be no guarantee of our ability to obtain or maintain patent protection for our products or product candidates. We cannot guarantee that we will be able to produce commercially successful products or maintain the commercial success of our existing products. Our stock price may be affected by actual or perceived market opportunity, competitive position, and success or failure of our products or product candidates. Further, the discovery of significant problems with a product similar to one of our products that implicate an entire class of products could have a material adverse effect on sales of the affected products and on our business and results of operations.

The scientific information discussed in this news release related to our product candidates is preliminary and investigative. Such product candidates are not approved by the U.S. Food and Drug Administration (FDA), and no conclusions can or should be drawn regarding the safety or effectiveness of the product candidates.

CONTACT: Amgen, Thousand Oaks
Ashleigh Koss, 805-559-0746 (media)
Arvind Sood, 805-447-1060 (investors)

1. &
'/>"/>

SOURCE Amgen
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology news :

1. Report presents designs for study of cancer risks near US nuclear facilities
2. NYU School of Medicine presents 2012 Dart/NYU Biotechnology Achievement Awards
3. John Theurer Cancer Center presents significant blood cancer research at 2012 ASCO Annual Meeting
4. GSA Bulletin presents studies in Antarctica, Italy, Mexico, Algeria, Mongolia, and more
5. Crop Science Society of America presents 2012 class of fellows
6. IOF Asia-Pacific Meeting presents new research and advances in osteoporosis management
7. Choline supplementation during pregnancy presents a new approach to schizophrenia prevention
8. July meeting presents animal and dairy science
9. Ludwig presents advancements in immunotherapy and epigenetics at the American Association for Cancer Research Annual Meeting
10. Beyond the microscope: Identifying specific cancers using molecular analysis
11. New analysis of premature infants heartbeats, breathing could be cues for leaving NICU
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... Technology Showcase, Hall E -   EyeLock Inc. , a ... will showcase its EyeLock ID technology integrated in a 3D ... Oak Ridge National Laboratory (ORNL) at the 2015 ... authentication technology is being used to validate the driver and ...
(Date:1/22/2015)... YORK , Jan. 21, 2015  Analyst Report Issued by ... Card Brands report showed that planet-wide, transactions at merchants on ... while the total number of credit, debit, and prepaid cards ... U.S. were victims of fraudulent card usage in 2012, and ...
(Date:12/24/2014)... , Dec. 23, 2014  Since its launch in December 2014, the ... eliminate the pain of trying to remember their usernames and ... fused to their smartphones. To assist people who have struggled ... company that created 1U and focuses on redefining identity, announced ...
Breaking Biology News(10 mins):EyeLock Debuts First Iris Authentication Technology Embedded in 3D Printed Automobile 2EyeLock Debuts First Iris Authentication Technology Embedded in 3D Printed Automobile 3$4.80 Near Term Price Target with "Buy" given by CapRock Research for NXT-ID, Inc. (NASDAQ: NXTD) issued by Small Cap IR 21U Offers Best Solution to the Username / Password Dilemma: For FREE! 21U Offers Best Solution to the Username / Password Dilemma: For FREE! 3
... one of the possible causes, of memory loss amongst ... proteins. The aim of this University of the ... location of certain proteins related to Alzheimers. The author ... her work is entitled, Alzheimer gaixotasunarekin erlazionatutako proteinen ultraegitura ...
... want to learn more? You probably aren,t watching television ... Professor Xiaoquan Zhao suggests that watching television has no ... climate change. Reading newspapers and using the web, however, ... The study, "Media Use and Global Warming Perceptions: ...
... This release is available in French . ... HIV-AIDS with interleukin-2 (IL-2) is ineffective. As a result, the ... Their finding was published in the New England Journal ... including Dr. Jean-Pierre Routy of the Research Institute of the ...
Cached Biology News:University of the Basque Country study on proteins related to Alzheimer's 2Television has less effect on education about climate change than other forms of media 2Research shows treating HIV-AIDS with interleukin-2 is ineffective 2
(Date:1/22/2015)... , Jan. 22. 2015  Varian Medical Systems (NYSE: ... been honored for its commitment to sustainability with inclusion on ... is the highest ranked healthcare equipment company among the Corporate ... the World Economic Forum at Davos, Switzerland ...
(Date:1/22/2015)... , Jan. 22, 2015  Derma Sciences, Inc. (Nasdaq: ... focused on advanced wound care, announces that AMNIOEXCEL® ... have been added to the Premier, Inc. Regenerative ... opportunity for the AMNIOEXCEL® and AMNIOMATRIX® product lines, ...
(Date:12/24/2014)...  United Therapeutics Corporation (NASDAQ: UTHR ) announced ... has submitted a pre-market approval application to the U.S. ... Medtronic,s SynchroMed ® II implantable drug infusion system ... Therapeutics, Remodulin ® (treprostinil) Injection delivered intravenously to ...
(Date:12/24/2014)... Texas , Dec. 24, 2014  Vermillion, Inc. ... on gynecologic disease, announced today that the Company ... including Oracle Investment Management, Jack W. Schuler ... Total proceeds were $10.5 million, before offering expenses.  ...
Breaking Biology Technology:Varian Honored Among World's 100 Most Sustainable Corporations 2Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 2Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 3Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 4Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 5United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 2United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 3United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 4Vermillion Announces Closing of Equity Financing 2Vermillion Announces Closing of Equity Financing 3
... , , LAGUNA HILLS, Calif., ... novel biopolymer implant therapies to treat cardiac abnormalities, announced today that ... , , CardioPolymers, Inc. Chief ... effective immediately, better reflects our focus on employing natural biocompatible polymer ...
... ... of Health to develop original in silico technologies to predict 3D structures of RNA-based molecules, ... , ... -- DNA Software, Inc. has been awarded three Fast Track SBIR grants from the National ...
... , PHILADELPHIA, July 22 ERT (Nasdaq: ... eClinical technology, ePRO, and other services to the biopharmaceutical, medical device, ... of Project Management, Tammy Miller. Ms. Miller will report to the ... role, Ms. Miller will be responsible for the global implementation and ...
Cached Biology Technology:Symphony Medical Changes Name to CardioPolymers, Inc. 2DNA Software, Inc. Awarded $2.5 M in NIH Funding to Develop Pioneering Nucleic Acid-based Technologies 2DNA Software, Inc. Awarded $2.5 M in NIH Funding to Develop Pioneering Nucleic Acid-based Technologies 3DNA Software, Inc. Awarded $2.5 M in NIH Funding to Develop Pioneering Nucleic Acid-based Technologies 4ERT Appoints New Vice President of Project Management 2ERT Appoints New Vice President of Project Management 3
Anti-Mouse Reticular Fibroblast, Purified (Clone ER-TR7) (rat IgG2a)...
...
...
... are predominantly used for labeling proteins, the ... peptides and nucleotides because they give better ... required in the conjugation processes. 5-TAMRA is ... peptides and proteins. 6-TAMRA is predominately used ...
Biology Products: